Introduction {#s1}
============

Primary aldosteronism (PA) is a major cause of secondary hypertension affecting 5--13% of hypertensive patients ([@B1]--[@B3]). The two principal forms of PA are bilateral adrenal hyperplasia (BAH) and aldosterone-producing adenoma (APA) accounting for 60--70 and 30--40% of all PA cases, respectively ([@B4]). Somatic mutations of *KCNJ5* (Potassium Voltage-Gated Channel Subfamily J Member 5) (Gly151Arg or Leu168ARg) gene are present in 34--43% of APAs ([@B5]--[@B9]). Mutations in *ATP1A1* (ATPase Na^+^/K^+^ transporting Subunit Alpha 1; in 5.3--17%), *ATP2B3* (ATPase Plasma Membrane Ca^++^ Transporting 3; in 1.7--4%), *CACNA1D* (Calcium Voltage-Gated Channel Subunit Alpha 1D; in 9.3--21%), and *CTNNB1* (Catenin Beta 1; in 2.1--5.1%) genes are responsible for a smaller portion of APAs ([@B10]--[@B14]). Nanba et al. found somatic mutations in aldosterone-driving genes in 88% of APAs by comprehensive NGS of CYP11B2 (aldosterone synthase)-expressing adrenal tumors ([@B13]). Moreover, tumors harboring *CACNA1D* mutation were found to be smaller than tumors with *KCNJ5* mutations ([@B14]). In contrast, the pathogenesis of BAH is largely unknown that is mostly related to the lack of tissue samples for analysis since it is mostly left unoperated.

Due to the difference in treatment strategies (surgical resection for APA, mineralocorticoid antagonists for BAH), differentiation of APA and BAH is of pivotal clinical relevance. Adrenal venous sampling (AVS) is considered to be the gold standard for the differentiation of the two clinical entities, but it is invasive, requires great expertise and unfortunately unavailable in many centers ([@B15]--[@B17]). The recent SPARTACUS trial has challenged the superiority of AVS over imaging, but its findings are debated ([@B18]). The need for a reliable and easily accessible diagnostic biomarker enabling their differentiation is critical to assure the best clinical management for patients with primary hyperaldosteronism.

MicroRNAs (miRNA, miR) in their mature forms are short (19--25 nucleotide long), single-stranded, non-coding RNA molecules involved in the gene expression mostly at the post-transcriptional level. MiRNAs are expressed in a tissue-specific manner ([@B19]), and are also secreted in various body fluids; as such, miRNAs hold promise as potential diagnostic biomarkers, as a component of liquid biopsy ([@B20], [@B21]). Our aim has been to perform profiling of circulating plasma miRNAs in AVS-confirmed samples of patients with primary hyperaldosteronism in order to determine biomarkers for differentiation of APA vs. BAH.

The aim of our study was to determine and compare the circulating microRNA expression profiles of APA and hyperplasia plasma samples, and to evaluate their applicability as minimally invasive markers in replacing AVS in the diagnostics of PA.

Materials and Methods {#s2}
=====================

Sample Collection and Ethics Approval
-------------------------------------

A total of 123 EDTA-anticoagulated plasma samples were used ([Table 1](#T1){ref-type="table"}). Altogether, 61 APA and 62 BAH samples were included in the study. Seventy-two male and Fifty-one female patients\' samples were included. The average age has been 54.17 for women and 49.39 for men. The sex of patients was not considered as a factor in the statistical analysis of the data. Diagnosis of PA was established according to current guidelines ([@B22]). APA and BAH were differentiated by AVS with or without ACTH stimulation ([Table 2](#T2){ref-type="table"}). Lateralization index (LI) was used to differentiate between the two entities \[(left side cortisol/left side aldosterone)/(right side cortisol/right side aldosterone)\]. If LI was between 0.33 and 3, the sample was considered as BAH, while if it was more than 4 or \<0.25, the sample was considered to be APA. Samples from APA patients were collected preoperatively. Genetic results of APA samples were available only for a minority of cases. Samples with lateralization index of 0.25--0.33 and 3--4 were considered to be in the zones of overlap, thus not included in the study ([@B23]). The study was approved by the Ethical Committee of the Hungarian Health Council. All experiments were performed according to relevant guidelines and protocols, and from all the involved patients written informed consent was obtained.

###### 

Patient data of the 123 samples included.

  **Sample**   **Diagnosis**   **Cohort**   **Age at diagnosis (range)**   **Tumor size (mm), laterality**   **Aldosterone AVS right nmol/L**   **Aldosterone AVS left nmol/L**   **Cortisol AVS right nmol/L**   **Cortisol AVS left nmol/L**   **Lateralization index**   **Date of sampling**
  ------------ --------------- ------------ ------------------------------ --------------------------------- ---------------------------------- --------------------------------- ------------------------------- ------------------------------ -------------------------- ----------------------
  1            BAH             NGS          40--45                         15, right                         22.27                              43.63                             62.39                           127.6                          1.04                       2018
  2            BAH             NGS          60--65                         Normal                            16.68                              12.69                             177.55                          121.33                         0.9                        2018
  3            BAH             NGS          30--35                         12, left                          24.52                              9.47                              67.61                           22.8                           0.87                       2018
  4            BAH             NGS          56--60                         10, right                         14.9                               9.35                              75.55                           52.13                          1.1                        2018
  5            BAH             NGS          36--40                         Normal                            15.31                              12.17                             175.13                          99.11                          0.71                       2018
  6            BAH             NGS          36--40                         Normal                            55.12                              54.66                             126.37                          115.2                          0.92                       2018
  7            BAH             NGS          40--45                         Normal                            26.42                              20.8                              339.67                          157.47                         0.59                       2018
  8            BAH             NGS          56--60                         Normal                            23.37                              14.92                             160.04                          84.86                          0.83                       2018
  9            BAH             NGS          65--70                         Normal                            7.82                               7.13                              99.8                            83.96                          0.92                       2018
  10           BAH             NGS          46--50                         10/19, right/left                 103.76                             42.45                             326.61                          225.48                         1.69                       2017
  11           BAH             NGS          60--65                         9/7, right/left                   44.39                              47.16                             176.54                          144.64                         0.77                       2016
  12           BAH             NGS          70--75                         5/15, right/left                  835.06                             882.23                            387.88                          249.76                         0.61                       2015
  13           BAH             NGS          66--70                         5/5, right/left                   174.78                             66.58                             256.29                          92.08                          0.94                       2015
  14           BAH             NGS          50--55                         16, left                          9.61                               6.39                              221.49                          167.48                         1.14                       2016
  15           APA             NGS          70--75                         Normal                            1.36                               24.33                             35.53                           17.4                           0.03                       2018
  16           APA             NGS          86--90                         15, right                         31.34                              1.32                              6.89                            6.53                           22.58                      2013
  17           APA             NGS          40--45                         12, left                          0.39                               38.9                              245.05                          276.23                         0.01                       2013
  18           APA             NGS          56--60                         12, left                          57.24                              5.28                              85.19                           193.94                         24.68                      2014
  19           APA             NGS          46--50                         15, right                         20.3                               4.4                               108.03                          160.23                         6.85                       2014
  20           APA             NGS          40--45                         10, left                          1.25                               225                               6.89                            12.33                          0.01                       2014
  21           APA             NGS          50--55                         Normal                            5.09                               236                               469.8                           482.85                         0.02                       2016
  22           APA             NGS          56--60                         8, right                          1170.76                            9.93                              327.7                           248.68                         89.45                      2017
  23           APA             NGS          30--35                         14, right                         108.2                              2                                 97.15                           27.55                          15.36                      2017
  24           APA             NGS          56--60                         29, right                         78.51                              2.64                              271.51                          81.56                          8.95                       2015
  25           APA             NGS          46--50                         5/5, right/left                   33.29                              169.23                            416.88                          160.23                         0.08                       2017
  26           APA             NGS          40--45                         10, right                         1942.01                            6.94                              369.75                          179.08                         135.61                     2017
  27           APA             NGS          50--55                         5/10, right/left                  0.39                               310.72                            5.44                            207.71                         0.05                       2016
  28           APA             NGS          46--50                         7/9, right/left                   61.03                              4.72                              315.01                          122.16                         5.02                       2015
  29           APA             NGS          56--60                         6/7, right/left                   55.49                              124.84                            213.51                          88.45                          0.18                       2016
  30           APA             NGS          60--65                         12, left                          30.52                              63.81                             219.31                          96.43                          0.21                       2017
  31           BAH             Validation   40--45                         Normal                            41.07                              13.69                             539.04                          214.6                          1.19                       2018
  32           BAH             Validation   30--35                         Normal                            48.49                              21                                390.78                          181.98                         1.08                       2018
  33           BAH             Validation   40--45                         Normal                            37.79                              13.6                              192.13                          101.86                         1.47                       2018
  34           BAH             Validation   70--75                         26, left                          65.99                              17.58                             553.9                           193.21                         1.31                       2018
  35           BAH             Validation   60--65                         23, left                          5.05                               38.09                             22.48                           170.01                         1                          2018
  36           BAH             Validation   46--50                         Normal                            33.69                              39.79                             328.79                          161.31                         0.42                       2018
  37           BAH             Validation   35--40                         Normal                            50.19                              41.29                             234.9                           312.84                         1.62                       2018
  38           BAH             Validation   60--65                         2, left                           18.3                               14.55                             174                             104.76                         0.76                       2018
  39           BAH             Validation   50--55                         20, right                         6.49                               3.9                               94.25                           106.58                         1.88                       2014
  40           BAH             Validation   36--40                         20, right                         0.33                               1.08                              4.21                            7.21                           0.52                       2015
  41           BAH             Validation   66--70                         7, left                           3.28                               5.68                              48.58                           36.61                          0.44                       2018
  42           BAH             Validation   60--65                         Normal                            0.5                                17.37                             15.23                           199.01                         0.38                       2014
  43           BAH             Validation   46--50                         Normal                            1.04                               3.38                              19.21                           56.91                          0.91                       2014
  44           BAH             Validation   56--60                         Normal                            66.03                              5.58                              537.23                          55.46                          1.22                       2014
  45           BAH             Validation   50--55                         15, left                          4.77                               13.07                             20.3                            89.18                          1.6                        2015
  46           BAH             Validation   40--45                         10, left                          0.69                               22.86                             17.04                           711.96                         1.26                       2015
  47           BAH             Validation   56--60                         Normal                            1.44                               1.56                              21.39                           20.3                           0.87                       2015
  48           BAH             Validation   46--50                         Normal                            3.72                               107.2                             67.06                           1255.71                        0.65                       2016
  49           BAH             Validation   50--55                         Normal                            17.01                              30.93                             176.9                           344.74                         1.07                       2016
  50           BAH             Validation   56--60                         Normal                            2.63                               3.97                              6.89                            11.24                          1.08                       2015
  51           BAH             Validation   40--45                         Normal                            9.73                               7.74                              10.88                           17.04                          1.97                       2013
  52           BAH             Validation   40--45                         Normal                            2.8                                4.26                              40.24                           95.34                          1.56                       2013
  53           BAH             Validation   36--40                         Normal                            6.18                               1.04                              233.09                          27.91                          0.71                       2012
  54           BAH             Validation   56--60                         7, right                          4.43                               12.13                             117.09                          208.8                          0.65                       2012
  55           BAH             Validation   50--55                         Normal                            4.82                               15.58                             199.01                          362.5                          0.56                       2011
  56           BAH             Validation   30--35                         Normal                            6.46                               1.14                              83.05                           19.68                          1.35                       2011
  57           BAH             Validation   40--45                         Left 1.3 cm                       1.62                               36.62                             40.6                            347.28                         0.38                       2011
  58           BAH             Validation   60--65                         Normal                            15.05                              9.95                              47.96                           61.66                          1.94                       2010
  59           BAH             Validation   40--45                         10, left                          5.27                               53.82                             11.64                           242.19                         2.04                       2010
  60           BAH             Validation   45--50                         Normal                            3.68                               2.44                              206.01                          244.47                         1.79                       2010
  61           BAH             Validation   36--40                         Normal                            12.06                              1.95                              10.95                           4.82                           2.73                       2011
  62           BAH             Validation   56--60                         10, right                         10.61                              10.85                             1382.95                         1027.7                         0.73                       2011
  63           BAH             Validation   50--55                         Normal                            2.5                                5.52                              52.24                           69.78                          0.6                        2014
  64           BAH             Validation   70--75                         Normal                            2.66                               2.27                              7.54                            10.19                          1.58                       2011
  65           BAH             Validation   50--55                         22/11, right/left                 5.31                               16.92                             6.45                            7.29                           0.35                       2013
  66           BAH             Validation   50--55                         Normal                            13.57                              8.54                              44.95                           33.02                          1.17                       2014
  67           BAH             Validation   66--70                         5, left                           92.8                               89.2                              696.37                          234.54                         0.35                       2018
  68           BAH             Validation   60--65                         7, left                           35.6                               18.22                             416.88                          199.74                         0.94                       2016
  69           BAH             Validation   36--40                         14/20, right/left                 83.5                               13.2                              508.95                          181.61                         2.26                       2018
  70           BAH             Validation   66--70                         15/10, right/left                 4.4                                1.7                               411.08                          235.63                         1.48                       2018
  71           BAH             Validation   66--70                         Normal                            43.35                              21.2                              411.44                          180.89                         0.9                        2018
  72           BAH             Validation   66--70                         7, right                          54.5                               43.2                              317.19                          85.19                          0.34                       2019
  73           BAH             Validation   66--70                         Normal                            99.87                              58.26                             511.13                          291.81                         0.98                       2018
  74           BAH             Validation   36--40                         Normal                            180.33                             21.08                             913.51                          296.89                         2.78                       2018
  75           BAH             Validation   36--40                         5, left                           44.39                              23.03                             114.91                          93.16                          1.56                       2018
  76           BAH             Validation   40--45                         11, left                          11.08                              12.07                             101.14                          128.33                         1.16                       2019
  77           BAH             Validation   50--55                         15, right                         44.08                              15.08                             247.73                          179.77                         2.12                       2019
  78           APA             Validation   60--65                         13, left                          125.98                             2.12                              355.98                          437.54                         73.05                      2018
  79           APA             Validation   50--55                         20, left                          4.82                               25.63                             330.96                          173.28                         0.1                        2018
  80           APA             Validation   20--25                         7, left                           25.2                               47.39                             808.02                          272.24                         0.18                       2018
  81           APA             Validation   50--55                         18, left                          7.2                                20.8                              238.53                          61.63                          0.09                       2018
  82           APA             Validation   46--50                         23/23, right/left                 0.84                               47.83                             39.51                           197.2                          0.09                       2018
  83           APA             Validation   60--65                         10, left                          5.92                               48.19                             175.09                          69.6                           0.05                       2018
  84           APA             Validation   56--60                         10, left                          16.9                               14.8                              379.54                          84.46                          0.25                       2018
  85           APA             Validation   56--60                         Normal                            19.3                               41.19                             630.03                          339.3                          0.25                       2018
  86           APA             Validation   30--35                         15, right                         18.34                              261.18                            116.98                          70.72                          0.04                       2018
  87           APA             Validation   40--45                         20, left                          6.63                               97.74                             191.8                           146.89                         0.05                       2018
  88           APA             Validation   56--60                         15, right                         393.95                             17.37                             184.51                          177.99                         21.88                      2015
  89           APA             Validation   56--60                         6/8, right/left                   10.26                              277.43                            193.21                          317.91                         0.06                       2015
  90           APA             Validation   40--45                         10, right                         163.68                             3.99                              164.94                          122.89                         30.53                      2016
  91           APA             Validation   30--35                         14, right                         108.2                              2                                 97.15                           27.55                          15.36                      2017
  92           APA             Validation   46--50                         10/15, right/left                 1.69                               88.78                             127.96                          124.34                         0.02                       2017
  93           APA             Validation   66--70                         12, right                         5.55                               33.29                             192.49                          126.51                         0.11                       2017
  94           APA             Validation   56--60                         13, left                          8.6                                244.14                            140.65                          95.34                          0.02                       2017
  95           APA             Validation   56--60                         10/5, right/left                  177.56                             11.93                             314.29                          287.1                          13.6                       2017
  96           APA             Validation   50--55                         Normal                            0.63                               6.61                              56.91                           14.61                          0.02                       2014
  97           APA             Validation   50--55                         Normal                            50.62                              5.93                              80.84                           266.08                         28.11                      2014
  98           APA             Validation   56--60                         16, right                         64.6                               1.67                              174                             268.25                         59.63                      2017
  99           APA             Validation   46--50                         15, right                         160                                1.55                              12.14                           35.71                          303.35                     2017
  100          APA             Validation   36--40                         13, left                          5.33                               62.01                             219.68                          175.09                         0.07                       2015
  101          APA             Validation   66--70                         Normal                            15.98                              1.13                              15.95                           104.76                         92.96                      2014
  102          APA             Validation   30--35                         13, right                         14.32                              1.32                              28.64                           86.28                          32.8                       2017
  103          APA             Validation   50--55                         Normal                            232.6                              0.62                              7.98                            5.8                            273.43                     2016
  104          APA             Validation   60--65                         Normal                            25.52                              1.31                              17.76                           63.8                           70.16                      2014
  105          APA             Validation   60--65                         20, left                          1.12                               38.51                             12.83                           24.14                          0.05                       2010
  106          APA             Validation   56--60                         hyperplasia                       8.73                               7.47                              527.44                          17.33                          0.04                       2010
  107          APA             Validation   56--60                         20/15, right/left                 41.76                              8.28                              572.75                          8.59                           0.08                       2011
  108          APA             Validation   36--40                         Hyperplasia                       1.49                               6.33                              10.66                           9.68                           0.21                       2013
  109          APA             Validation   50--55                         40, left                          1.35                               49.07                             78.3                            119.63                         0.04                       2012
  110          APA             Validation   56--60                         Normal                            0.83                               97.93                             350.18                          209.89                         0.01                       2014
  111          APA             Validation   46--50                         20, left                          1.12                               44.72                             185.31                          210.83                         0.03                       2015
  112          APA             Validation   40--45                         Normal                            9.73                               7.74                              10.95                           16.97                          1.95                       2013
  113          APA             Validation   36--40                         16, right                         133.12                             0.35                              180.13                          42.74                          91.08                      2009
  114          APA             Validation   26--30                         16, left                          3.16                               20.91                             696.73                          441.17                         0.1                        2011
  115          APA             Validation   56--60                         12/5, right/left                  280.2                              10.71                             254.11                          205.54                         21.16                      2018
  116          APA             Validation   46--50                         14, left                          8.46                               372.42                            398.03                          379.9                          0.02                       2018
  117          APA             Validation   36--40                         6/11, right/left                  9.99                               99.87                             225.48                          204.45                         0.09                       2018
  118          APA             Validation   60--65                         5/12, right/left                  19.7                               55.49                             265.35                          163.49                         0.22                       2018
  119          APA             Validation   50--55                         14/13, right/left                 61.03                              224.72                            179.8                           84.1                           0.13                       2018
  120          APA             Validation   56--60                         9/5, right/left                   1417.67                            3.83                              226.56                          82.29                          134.49                     2019
  121          APA             Validation   46--50                         18, left                          22.97                              41.71                             89.14                           33.42                          0.21                       2019
  122          APA             Validation   66--70                         21, right                         55.83                              1.34                              70.76                           31.39                          18.52                      2019
  123          APA             Validation   60--65                         normal                            116.48                             19.41                             195.21                          134.49                         4.13                       2019

*APA, aldosterone-producing adenoma; AVS, adrenal vein sampling; BAH, bilateral adrenal hyperplasia*.

###### 

List of centers providing samples for the study and AVS strategy.

  **Country/Center**   **Sample number**   **AVS protocol**
  -------------------- ------------------- ------------------
  USA/Rochester        30                  ACTH stimulated
  Italy/Turin          17                  ACTH stimulated
  Italy/Padova         13                  ACTH stimulated
  Croatia/Zagreb       22                  ACTH stimulated
  Germany/Munich       41                  Unstimulated

*ACTH, adrenocorticotropic hormone; AVS, adrenal vein sampling*.

Sample Processing
-----------------

Total RNA isolation was carried out from all plasma samples by miRNeasy Serum/Plasma Kit (Qiagen GmbH, Hilden, Germany). For assessing recovery efficacy, 5 μL of 5 nM Syn-cel-miR-39 miScript miRNA Mimic (Qiagen GmbH) was added before the addition of acid-phenol/chloroform as a spike-in control. Total RNA was held frozen at −80°C until further use.

miRNA Expression Profiling From Plasma Samples by Next-Generation Sequencing (NGS)
----------------------------------------------------------------------------------

A total of 30 samples (16 APA and 14 BAH) were subjected to NGS. APA samples showing the highest (\>4) or lowest (\<0.25) LI and BAH samples with LI closest to 1 were selected for this cohort. Samples were involved from 3 centers (9, 13, 8 samples, respectively; 22 males and 8 females; average age BAH: 53.28 years, APA: 54.46 years). cDNA library was made from total RNA by the QIAseq miRNA Library Kit (Qiagen GmbH) according to the manufacturer\'s guideline. The library was prepared for sequencing in accordance with the instructions of the MiSeq Reagent Kit v3 (Illumina, San Diego, CA, USA). NGS was performed by Illumina MiSeq (Illumina). FASTQ files were used in the primary data analysis procedure, in which online analysis software of Qiagen was applied (<https://geneglobe.qiagen.com/sg/analyze/>). To strengthen our findings, another statistical method was also applied. Primary analysis included trimming of adapters using cutadapt (Marcel Martin, Technical University, Dortmund, Germany); reads with \<16 bp insert sequences or with \<10 bp Unique Molecular Index were discarded. Alignment of reads was performed using bowtie (John Hopkins University, Baltimore, MD, USA), and miRBase V21 was used for miRNAs. Secondary analysis revealed significantly differently expressed miRNAs after DESeq2 normalization ([@B24]). Disease groups were compared by unpaired Mann--Whitney test, and to decrease the false discover rate, corrected *p*-value was calculated by Benjamini--Hochberg method.

Validation of Individual miRNAs
-------------------------------

miRNAs significantly differentially expressed by NGS were validated by RT-qPCR on an independent validation cohort of 93 samples in one center (Semmelweis University, 2nd Department of Internal Medicine). Reverse transcription of RNA was performed using the TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) and individual TaqMan miRNA assays (CN: 4427975, 4440886; Thermo Fisher Scientific). Selected miRNAs were *hsa-miR-30e-5p* (ID: 002223), *hsa-miR-223-3p* (ID: 002295), *hsa-miR-30d-5p* (ID: 000420), and *hsa-miR-7-5p* (ID: 005723_mat). As reference miRNA, *cel-miR-39* (ID: 000200) was used. Quantitative real-time PCR was performed by the TaqMan Fast Universal PCR Master Mix (2x) (CN: 4352042; Thermo Fisher Scientific) on a Quantstudio 7 Flex Real-Time PCR System (Thermo Fisher Scientific) in accordance with the manufacturer\'s protocol for TaqMan miRNA assays with minor modifications (the end volume of the reaction was 15 μl, program of thermal cycler was the following: after 20 s on 95°C, 40 cycles of 95°C for 3 s and 60°C for 30 s). Negative control reactions contained no cDNA templates. Samples were always run in triplicate. For data evaluation, the dCt method \[delta Ct (cycle threshold) value equals target miRNA\'s Ct minus internal control miRNA\'s Ct\] was used by Microsoft Excel 2016 (Microsoft, Redmond, WA, USA).

Statistical Analysis
--------------------

Statistical power analysis was calculated with a statistical power and sample size calculator (HyLown Consulting LLC, Atlanta, GA, USA) ([@B25]). RT-qPCR data analysis was performed by GraphPad Prism 7.00 (GraphPad, La Jolla, CA, USA). Being a multicenter study, comparative statistics (Kruskal--Wallis test) were performed on samples from same disease groups, but from different centers in order to find possible skewed results. For differentiating between APA and BAH groups, *t*-test with Welch\'s correction or Mann--Whitney test based on the result of the Shapiro--Wilk normality test. To exclude skewed results, --dCt values were standardized using standard score (*z*-value, *z*-score: $z = \frac{x - \mu}{\sigma}$, where μ and σ is the mean and standard deviation of values of the given center, respectively. The *F*-test was used to evaluate differences between variances of circulating miRNA expressions of APA and BAH. Receiver operating characteristic (ROC) analysis was performed on miRNAs that could have potential utility as minimally invasive biomarkers. *P* \< 0.05 were considered significant.

Results {#s3}
=======

miRNA Expression Profiling by NGS
---------------------------------

We found 50 miRNAs to be significantly differentially expressed in samples of patients with APA vs. samples of patients with BAH by NGS and analyzed with the Qiagen online software. Multiple statistical analysis (including unpaired Mann--Whitney test) was performed on primary data that resulted in nine miRNAs showing the highest levels of significance ([Table 3](#T3){ref-type="table"}). From these, four miRNAs with the highest significance i.e., *hsa-miR-30e-5p* (*p*-value: 0.0005), *hsa-miR-223-3p* (*p*-value: 0.0039)*, hsa-miR-30d-5p* (*p*-value: 0.0091), and *hsa-miR-7-5p* (*p*-value: 0.0134) were selected for validation on an independent cohort of samples. Statistical power analysis showed that by using this cohort of samples, the power of the sequencing was above 0.99. NGS data are available under the Gene Expression Omnibus (GEO) accession number [GSE126386](GSE126386).

###### 

List of 9 miRNAs with the most significant differences in expression between APA and BAH samples.

  **miRNA**            ***p*-value**
  -------------------- ---------------
  **hsa-miR-30e-5p**   **0.000506**
  **hsa-miR-223-3p**   **0.003865**
  **hsa-miR-30d-5p**   **0.009064**
  **hsa-miR-7-5p**     **0.013403**
  hsa-let-7d-3p        0.024542
  hsa-miR-16-5p        0.038273
  hsa-miR-19b-3p       0.042548
  hsa-miR-339-3p       0.042548
  hsa-miR-22-3p        0.047205

*In bold, the four microRNAs with the highest level of significance that have been subjected to validation*.

Real-Time qPCR Validation of Selected miRNAs
--------------------------------------------

Four miRNAs, *hsa-miR-7-5p, hsa-miR-30d-5p, hsa-mir-30e-5p*, and *hsa-miR-223-3p* were subjected to validation by real-time RT-qPCR on 93 samples. Differences between miRNA expression within the investigated disease groups (APA and BAH) between different centers could be demonstrated (*p* \< 0.0001), but the higher expression of miRNA in BAH relative to APA is evident for most cases ([Figure 1](#F1){ref-type="fig"}). To exclude distorted results, standard scores of miRNA expression values of APA and BAH samples were compared ([Figure 2](#F2){ref-type="fig"}). Validation of three out of four miRNAs established as significant by NGS were successful. *Hsa-miR-30e-5p* (*p* = 0.04) ([Figure 2A](#F2){ref-type="fig"}), *hsa-miR-30d-5p* (*p* = 0.02) ([Figure 2C](#F2){ref-type="fig"}), and *hsa-miR-7-5p* (*p* = 0.016) ([Figure 2D](#F2){ref-type="fig"}) were significantly upregulated in BAH in comparison with APA samples. An upregulation tendency of *hsa-miR-223-3p* in BAH samples relative to APA samples was noticeable, but not significant (*p* = 0.15) ([Figure 2B](#F2){ref-type="fig"}). As shown on [Figure 1](#F1){ref-type="fig"} regarding the relative differences between standard deviations, BAH samples appear to be homogenous at the level of miRNA expression, while miRNA expression in APA samples are more heterogeneous. To evaluate difference between variances of sample groups we applied *F*-test. *P*-values for *hsa-miR-7-5p* were: Zagreb: 0.35; Rochester: 0.055; Padova: n.d.; Turin: 0.03; Munich: 0.24, if *p* \< 0.05, null-hypothesis is rejected, therefore standard deviations are surely not equal. Relative miRNA expression did not correlate with any of the measured parameters (tumor diameter, lateralization index, aldosterone ratio between two sides at AVS, basal peripheral aldosterone) and no sex difference was observed.

![Results of RT-qPCR of the four miRNAs selected for validation from each sample contributing center. Mean ± Standard deviation (SD) of -dCT values of selected miRNAs; **(A)** *hsa-miR-30e-5p*; **(B)** *hsa-miR-223-3p*; **(C)** *hsa-miR-30d-5p*; **(D)** *hsa-miR-7-5p*. Significant differences can be seen among the APA or BAH samples from different centers (ANOVA or Kruskal--Wallis test based on the result of Shapiro--Wilks normality test). ^\*\*\*\*^*p* \< 0.0001.](fendo-10-00739-g0001){#F1}

![Results of RT-qPCR of the four miRNAs selected for validation. Mean ± Standard deviation (SD) of standard scores of -dCT values of selected miRNAs; **(A)** *hsa-miR-30e-5p*; **(B)** *hsa-miR-223-3p*; **(C)** *hsa-miR-30d-5p*; **(D)** *hsa-miR-7-5p*. Student\'s *t*-test with Welch correction or Mann--Whitney test was used based on the result of the Shapiro--Wilks normality test. ^\*^*p* \< 0.05.](fendo-10-00739-g0002){#F2}

Diagnostic Performance of Circulating miRNAs
--------------------------------------------

The diagnostic utility of the three significantly differentially expressed circulating microRNAs, *hsa-miR-7-5p, hsa-miR-30e-5p*, and *hsa-miR-30d-5p* was evaluated by ROC analysis ([Figure 3](#F3){ref-type="fig"}). For *hsa-miR-7-5p*, the area under curve (AUC) was 0.64, and specificity and sensitivity values were 61.7 and 58.7%, respectively when choosing 0.13 as a cut-off point. ROC-analysis of *hsa-miR-30e-5p* showed an AUC of 0.61, and sensitivity of 58.7% and specificity of 61.7% when choosing 0.06 as a cut-off point. *Hsa-miR-30d-5p* performed similarly to *hsa-miR-7-5p* on ROC-analysis, AUC: 0.64, sensitivity: 58.7% and specificity: 61.7% when choosing a cut-off point of 0.05.

![Evaluation of the diagnostic applicability of **(A)** *hsa-miR-7-5p*, **(B)** *hsa-miR-30e-5p*, and **(C)** *hsa-miR-30d-5p* by receiver operating characteristic (ROC) curves. AUC = area under curve.](fendo-10-00739-g0003){#F3}

Discussion {#s4}
==========

Several genes have been described to be involved in the pathogenesis of APA, but the pathogenesis of BAH remains elusive. A recent study reported that aldosterone-producing cell clusters can be detected in BAH, and in these *CACNA1D* and *KCNJ5* mutations were found ([@B26]). BAH could be associated with bilateral microscopic hyperplasia, bilateral nodular hyperplasia, bilateral adenomas, or bilateral adrenal aldosterone-producing cell clusters ([@B27]). Based on recent data, the various forms of PA can be regarded as representatives of a spectrum of diseases of variable severity ([@B28], [@B29]).

From a clinical perspective, differentiation of a unilateral APA from a bilateral hyperplasia is of pivotal importance, as their treatment is different (operation vs. medical therapy). AVS is the gold standard, but it is not widely available, it is invasive and requires great expertise. A minimally invasive marker for differentiating these two entities would be an invaluable help in the management of PA. We have therefore examined the expression of circulating miRNA in AVS-confirmed APA and BAH samples to evaluate the applicability of these novel epigenetic markers for their differentiation.

In our study, 50 miRNAs showed some degree of significantly different expression by NGS, and from the four miRNA selected for validation, three circulating miRNAs *hsa-miR-30e-5p, hsa-miR-30-5p*, and *hsa-miR-7-5p* were confirmed to be significantly up-regulated in BAH in comparison with APA (the fourth studied miRNA *hsa-miR-223-3p* showed only a non-significant tendency of up-regulation in BAH). In a previous study of miRNA expression in PA, where the authors compared tissue miRNA expression profiles of APA, unilateral adrenal hyperplasia (UAH) and normal adrenal cortex, *hsa-miR-375* and *hsa-miR-7* were significantly underexpressed in APA when compared to UAH and normal adrenal glands ([@B30]). Moreover, in a recent study, three of our selected circulating miRNAs *hsa-miR-30e-5p, hsa-miR-30d-5p*, and *hsa-miR-223-3p* were found to be down-regulated in essential hypertension patients compared to healthy people\'s plasma samples ([@B31]). These observations could raise the possibility that these miRNAs might be related to the regulation of blood pressure.

The range of expression of all four validated miRNAs seems to be broader in APA samples than in BAH samples (*F*-test was significantly different for data of two centers, and a tendency was seen in another). This finding might be related to the observations, that APA is genetically more heterogeneous than BAH ([@B10], [@B11]).

It is unclear why the expression levels (represented by dCt values) in the APA and BAH groups from different centers contributing to our study are different. The tendency of up-regulation of miRNA in BAH relative to APA can be seen for most miRNAs, however, the expression levels were rather different between some centers ([Figure 1](#F1){ref-type="fig"}). Pre-analytical differences such as sample taking/storage might be suspected.

Despite showing significant overexpression in BAH samples, the diagnostic accuracy of the three validated circulating miRNAs (*hsa-miR-30e-5p, hsa-miR-30-5p*, and *hsa-miR-7-5p*) does not make them suitable for introduction to clinical practice. In contrast, adrenal venous sampling has impressive sensitivity and specificity values--when lateralization index cut-off point is 4--with 95.2 and 100%, respectively ([@B23]).

The pathogenic relevance of these miRNA in PA is unclear. Circulating *hsa-miR-7-5p* is found to be underexpressed in idiopathic inflammatory myopathy and esophageal squamous cell cancer patients compared to healthy controls ([@B32], [@B33]). Overexpressed *hsa-miR-7-5p* was found in acute pancreatitis, neuroendocrine tumors, and type 2 diabetes mellitus patients compared to healthy controls ([@B34]--[@B36]). There are reports stating that *hsa-miR-7-5p* functions as a tumor suppressor miRNA in pancreatic ductal adenocarcinoma ([@B37]) and in bladder cancer ([@B38]), and also inhibits melanoma cell proliferation ([@B39]). Circulating *hsa-miR-30e-5p* is up-regulated in systemic lupus erythematosus patients ([@B40]) and down-regulated in patients with mitral chord rupture ([@B41]) compared to healthy controls. Tissue *hsa-miR-30d-5p* is considered as a tumor suppressor miRNA in non-small cell lung cancer compared to healthy controls ([@B42]).

There are limitations of our study. Even if adrenal imaging was performed for all patients, due to the limited sensitivity of computed tomography and magnetic resonance imaging, bilateral adrenal microadenomas can be classified as bilateral hyperplasia. Actually, as the group of William E. Rainey has recently shown ([@B26]), BAH usually contains microadenomas, and thus the boundary between APA and BAH is not clear, and these PA forms can be regarded as representatives of the same spectrum of diseases. The clinical relevance, however, is still to be able to differentiate unilateral from bilateral forms. It would also be interesting to assess the circulating miRNA expression profiles related to different genetic forms of APA, but this would exceed the scope of our present study where the comparison of unilateral with bilateral forms of APA has been the primary aim for evaluating the potential applicability of circulating miRNA as markers of lateralization. Heterogeneity among contributing centers is another limitation, as discussed above.

To summarize, we have found that three circulating microRNAs were significantly overexpressed in BAH compared to APA patients, but don\'t have high enough sensitivity and specificity values to be introduced to clinical medicine. BAH seems to be more homogeneous in miRNA expression than APA. These findings also seem to support the idea that APA and BAH represent entities forming part of a spectrum of diseases leading to primary aldosteronism.
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